SLU-PP-332 is a synthetic small-molecule agonist of estrogen-related receptors (ERRα, ERRβ, and ERRγ). It is primarily a research compound, not an approved drug or dietary supplement. Its main value is as a tool for studying exercise-like metabolic adaptations.
1. Exercise-mimetic research
SLU-PP-332 is used experimentally to investigate whether activation of ERRs can reproduce some molecular effects of aerobic exercise. In mice, it activated an ERRα-dependent exercise-response gene program and improved exercise endurance.
2. Skeletal-muscle metabolism
Research uses it to study:
- mitochondrial function
- cellular respiration
- oxidative muscle fibers
- fatty-acid utilization
- skeletal-muscle metabolic adaptation
Treatment increased mitochondrial activity and promoted type IIa oxidative muscle fibers in experimental models.
3. Exercise endurance research
SLU-PP-332 has been investigated as a pharmacological means of increasing aerobic exercise capacity/endurance. This effect appears to depend substantially on ERRα activation.
4. Obesity and fat-metabolism research
In obese mouse models, SLU-PP-332 increased energy expenditure and fatty-acid oxidation and reduced fat-mass accumulation. Consequently, it is being investigated as a potential approach for understanding pharmacological interventions against obesity.
5. Metabolic syndrome and insulin sensitivity
Experimental studies have examined SLU-PP-332 for conditions associated with metabolic syndrome. In mouse models, treatment improved glucose tolerance and insulin sensitivity while altering whole-body energy metabolism.
6. Mitochondrial and aging research
Because ERR signaling is strongly involved in oxidative metabolism, SLU-PP-332 is useful for investigating mitochondrial function, muscle aging, metabolic decline, and exercise-related adaptations. Reviews describe ERR activation as a potential strategy for muscle-related and age-associated metabolic disorders, although clinical evidence is still lacking.
7. Cardiometabolic disease research
More broadly, ERR agonists are being investigated for potential applications involving:
- Obesity
- type 2 diabetes/metabolic dysfunction
- impaired mitochondrial metabolism
- reduced muscle function
- cardiovascular metabolic stress
These are preclinical research applications, rather than established clinical uses.
Summary
| Research use | Evidence |
| Exercise mimetic | Strong preclinical evidence |
| Increased endurance | Mouse studies |
| Mitochondrial activation | Cell + animal studies |
| Fatty-acid oxidation | Animal studies |
| Obesity reduction | Mouse models |
| Improved insulin sensitivity | Mouse models |
| Muscle aging research | Preclinical/potential |
| Human therapeutic use | Not established |
Important: SLU-PP-332 should not be regarded as a human “exercise replacement.” The published evidence is predominantly from cell and animal experiments, and human efficacy and safety have not been established. It is also relevant to sports-doping research because exercise mimetics such as SLU-PP-332 are prohibited by WADA.